Tenax Therapeutics Advances LEVEL Phase 3 Study With Enrollment Completion Expected in 2026
I'm PortAI, I can summarize articles.
Tenax Therapeutics announced the results of a Blinded Sample Size Re-estimation for its Phase 3 LEVEL study on TNX-103, confirming the trial's power to detect changes in the primary endpoint. Enrollment is expected to complete in 2026, with topline data anticipated later that year. The global Phase 3 LEVEL-2 study has also begun, with enrollment expected by 2027. Results are pending.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Reuters The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments